Investors
Rewrite disease. Measure outcomes.
We reprogram malignant and senescent cells, then prove the change with real‑time diagnostics and transparent milestones.
Preclinical in-vivo efficacy towards GBM readouts
AgeQuant vs traditional lab workflows
Oncology, senolytics, diagnostics
Why now
Epigenetic dysregulation is tractable; delivery matured; diagnostics are fast and inexpensive.
What’s different
We rewrite malignant and senescent programs then prove it with real‑time readouts.
Traction
Dated preclinical milestones, platform validation, and cost/time compression in diagnostics.
Pipeline
Cancer reprogramming (E‑ON‑001), senolytics (PCC1), AgeQuant diagnostics platform.
Regulatory & Risk
Clear paths for GBM and aging indications with safety‑first dosing and delivery.
IP & Economics
Filed/issuing claims; platform leverage; diagnostics as readout flywheel.
Milestones & Use of Funds
GBM in‑vivo efficacy update
Extended survival and functional markers in model
AgeQuant panel expansion
Inflammation + environmental toxins validation
PCC1 safety window
Dose‑response and tissue selectivity
Interested in the detailed plan, data, and timelines?
Request data room access